Moderna (NASDAQ:MRNA) Receives a Downgrade
BidaskScore cut Moderna (NASDAQ:MRNA) shares to a Hold rating in a research report published today.
The stock decreased 8.24% or $1.7 during the last trading session, reaching $18.94. About 3.54M shares traded or 48.10% up from the average. Moderna, Inc. (NASDAQ:MRNA) has 0.00% since December 7, 2018 and is . It has by 0.00% the S&P500.
Analysts await Moderna, Inc. (NASDAQ:MRNA) to report earnings on March, 11. After $-0.37 actual EPS reported by Moderna, Inc. for the previous quarter, Wall Street now forecasts 2.70 % negative EPS growth.
Moderna, Inc. develops medicines based on messenger RNA . The company has market cap of $6.30 billion. The Company’s pipeline includes development candidates for mRNA vaccines and therapies for use in various therapeutic areas comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. It currently has negative earnings. The firm was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.
More notable recent Moderna, Inc. (NASDAQ:MRNA) news were published by: Benzinga.com which released: “24 Stocks Moving in Friday’s Pre-Market Session – Benzinga” on November 29, 2019, also Streetinsider.com with their article: “UPDATE: BofA/Merrill Lynch Reinstates Moderna (MRNA) at Buy – StreetInsider.com” published on December 03, 2019, Nasdaq.com published: “Is CRISPR Therapeutics the Best Gene-Editing Stock Right Now? – Nasdaq” on November 26, 2019. More interesting news about Moderna, Inc. (NASDAQ:MRNA) were released by: Finance.Yahoo.com and their article: “Hedge Funds Are Way More Bullish On PG&E Corp Than These Stocks – Yahoo Finance” published on November 30, 2019 as well as Nasdaq.com‘s news article titled: “Top Ranked Momentum Stocks to Buy for November 8th – Nasdaq” with publication date: November 08, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.